5.13
-0.04(-0.77%)
Currency In USD
| Previous Close | 5.17 |
| Open | 5.07 |
| Day High | 5.21 |
| Day Low | 5.03 |
| 52-Week High | 19.8 |
| 52-Week Low | 2.69 |
| Volume | 14,838 |
| Average Volume | 121,288 |
| Market Cap | 13.73M |
| PE | -0.2 |
| EPS | -25.97 |
| Moving Average 50 Days | 5.34 |
| Moving Average 200 Days | 8.02 |
| Change | -0.04 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $21.48 as of August 24, 2025 at a share price of $5.13. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $47.98 as of August 24, 2025 at a share price of $5.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
GlobeNewswire Inc.
Jun 16, 2025 11:05 AM GMT
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Initial Phase 1
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 20